Impact of chemotherapy on venous thromboembolism. Comment to: Regional lymph node metastases are a strong risk factor for venous thromboembolism: Results from the Vienna Cancer and Thrombosis Study

Haematologica

Volumn 98, Issue 12, 2013, Pages

  Ferroni, Patrizia ^a   Riondino, Silvia ^a   Guadagni, Fiorella ^a   Roselli, Mario ^b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Disease stage; Hemostatic activation; Venous thromboembolism

Indexed keywords

BEVACIZUMAB; FLUOROPYRIMIDINE; GEMCITABINE;

ADULT; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEMOSTASIS; HUMAN; KAPLAN MEIER METHOD; LETTER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; VENOUS THROMBOEMBOLISM;

DISEASE STAGE; HEMOSTATIC ACTIVATION; VENOUS THROMBOEMBOLISM;

FEMALE; HUMANS; MALE; NEOPLASMS; VENOUS THROMBOEMBOLISM;

EID: 84889771804     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.092528     Document Type: Letter

References (13)

1. Dickmann B, Ahlbrecht J, Ay C, Dunkler D, Thaler J, Scheithauer W, et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica. 2013;98(8):1309-1314.
2. Rak J, Yu JL, Luyendyk J, Mackman N. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res. 2006;66(22):10643-10646.
3. Gil-Bernabé AM, Serena Lucotti S, Ruth J, Muschel RJ. Coagulation and metastasis: what does the experimental literature tell us? Br J Haematol. 2013;162(4):433-441.
4. Roselli M, Mineo TC, Basili S, Martini F, Mariotti S, Aloe S, et al. Soluble CD40 ligand (sCD40L) plasma levels in lung cancer. Clin Cancer Res. 2004;10(2):610-614.
5. Ferroni P, Martini F, Portarena I, Massimiani G, Riondino S, La Farina F, et al. Novel High-Sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in lung cancer patients. Clin Lung Cancer. 2012;13(6):482-487.
6. Ferroni P, Riondino S, Portarena I, Formica V, La Farina F, Martini F, et al. Association between increased tumor necrosis factor-alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer. Int J Colorectal Dis. 2012;27(12):1561-1567.
7. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and Predictors of Venous Thromboembolism (VTE) Among Ambulatory High-Risk Cancer Patients Undergoing Chemotherapy in the United States. Cancer. 2013;119(3):648-655.
8. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458-464.
9. Roselli M, Ferroni P, Riondino S, Mariotti S, Laudisi A, Vergati M, et al. Impact of chemotherapy on activated protein C-dependent thrombin generation Association with VTE occurrence. Int J Cancer. 2013;133(5):1253-1258.
10. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Am Med Ass. 2005;293(6):715-722.
11. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006;118(5):555-568.
12. Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291-292.
13. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.